Life Sciences Industry News – Page 9

SEC adopts McAdams and Hollingsworth proposal to cut red tape on promising start-ups

Posted on March 25, 2020 by Denise Bell

Courtesy of mcadams.house.gov Washington, D.C.—Legislation by Congressman Ben McAdams and Congressman Trey Hollingsworth (R-IN) giving commonsense regulatory relief for America’s growing companies was essentially adopted by the Securities and Exchange Commission (SEC) in a rule-making action. McAdams introduced the Fostering Innovation Act in 2019 as a narrow fix that allows small emerging growth companies to keep capital […]

BioUtah COVID-19 Life Sciences Survey

Posted on March 26, 2020 by Kelvyn Cullimore

TIME SENSITIVE – PLEASE TAKE SURVEY Dear Members of Utah’s Life Sciences Community, BioUtah is taking a multi-pronged approach to support our life sciences companies, industry workforce, and communities during the COVID-19 pandemic, including: Working directly with the Utah State Coronavirus Task Force to identify products and resources needed in the state Indentifing funding sources from […]

The Department of Health and Human Services on PREP

Posted on March 26, 2020 by Denise Bell

The Department of Health and Human Services issued a declaration on March 16 under the Public Readiness and Emergency Preparedness (“PREP”) Act to provide immunity to liability for activities related to medical countermeasures against COVID-19. The declaration is effective retroactively to February 4, 2020. The notice will be published in the Federal Register March 17. […]

BioUtah Statement & Recommendations to Members on COVID-19

Posted on March 26, 2020 by Kelvyn Cullimore

The advent and progression of the Novel Coronavirus, COVID-19, pandemic requires a proper and measured response from every company and every employee. The impact of the spread of this virus is being reflected in the stock market, reductions in travel, supply chain management, sporting events, education and mass gatherings of every kind. While the effects […]

PRESIDENT TRUMP SIGNS $8.3 BILLION CORONAVIRUS FUNDING BILL

Posted on March 26, 2020 by admin

Today, President Trump sign a $8.3 billion emergency coronavirus funding measure, after it cleared both the House and Senate earlier in the week. View a summary of the legislation here. The bill would provide funding for diagnostics, treatments, and the purchase of medical supplies. […]

Co-Diagnostics, Inc. Invited to Speak on Coronavirus at Molecular Med Tri-Con in San Francisco

Posted on March 26, 2020 by Denise Bell

March 03, 2020 06:30 AM Eastern Standard Time SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests and that recently reported it had received a CE marking for its COVID-19 coronavirus assay, announced today that it has been requested to speak at […]

BioUtah and the TVC Announce Keynote Speakers for the 2020 E & I Life Science Summit

Posted on February 21, 2020 by Denise Bell

Founder and CEO of Tolero Pharmaceuticals, David Bearss, Ph.D, and Managing Director and Head of Global Investment Opportunities Group of J.P. Morgan, Monica DiCenso, to address healthcare innovation and industry outlook at February 28 noted Utah life sciences event SALT LAKE CITY–(BUSINESS WIRE)–BioUtah, Utah’s only trade association dedicated solely to the life sciences, in partnership […]

ABC 4 Utah Features E&I Summit

Posted on February 20, 2020 by Denise Bell

ABC 4’s Good Morning Utah featured the 2020 Entrepreneur & Investor Summit this morning, sitting down with Keith Marmer, Executive Director of TVC at the University of Utah and the Salt Lake City Department of Economic Development’s Peter Makowski. The E&I Summit is Utah’s premier event for investment in the life sciences industry, bringing together up-and-coming companies, […]

BioUtah Enters M.O.U. with Hangshou Yuhang Economic-Technological Development Area

Posted on February 7, 2020 by Denise Bell

An MOU was signed between the Hangzhou District, World Trade Center Utah and BioUtah indicating a desire to work together for the common good of all parties. […]

Antibiotic-Resistant “Superbugs” – Public Health Crisis and Research Challenge

Posted on January 10, 2020 by Denise Bell

Antimicrobial Resistance (AMR) is a public health crisis, but developing new classes of antibiotics to combat drug resistant bacteria is challenging on many levels. Last month, the New York Times reported on the struggles facing companies that are researching new antibiotics. In November, the Centers for Disease Control and Prevention (CDC) released a report, Antibiotic Resistance […]

Red Tape Reduction: FDA Issues List of 510(k) Device Exemptions

Posted on January 3, 2020 by Denise Bell

On December 30, the FDA issued a notice (see the FDA’s Federal Register notice) that exempts certain class I and II medical devices from 510(k) premarket notification requirements. The exemptions, some of which are limited, cover a wide range of different products, including clinical chemistry test systems, clinical laboratory instruments, clinical toxicology test systems, hematology […]

Congress Reconvenes: Drug Pricing, USMCA updates

Posted on January 3, 2020 by Denise Bell

Congress returned yesterday with a number of big ticket items on their plate, including drug pricing and the U.S.-Mexico-Canada Agreement (USMCA), both of which have implications for Utah’s life sciences industry. Drug Pricing As the House of Representatives was passing the Democrat drug pricing plan, H.R. 3, the Lower Drug Prices Now Act, in the […]